Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Documenti analoghi

• Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
  di: Shrimanker, R, et al.
  Pubblicazione: (2019)
• Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
  di: Gunsoy, N, et al.
  Pubblicazione: (2017)
• Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
  di: Steven W. Yancey, et al.
  Pubblicazione: (2019-09-01)
• Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
  di: Howell, I, et al.
  Pubblicazione: (2024)
• Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
  di: Bel, E, et al.
  Pubblicazione: (2014)